Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention (X-PLORER)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01442792
First received: August 18, 2011
Last updated: April 1, 2014
Last verified: April 2014

August 18, 2011
April 1, 2014
October 2011
January 2013   (final data collection date for primary outcome measure)
  • The percentage of subjects who require bail-out anticoagulant therapy in the context of an ischemic coronary event [ Time Frame: During the index Percutaneous Coronary Intervention procedure ] [ Designated as safety issue: No ]
  • The percentage of subjects who experience an angiographic flow limiting thrombotic event [ Time Frame: During the index Percutaneous Coronary Intervention procedure ] [ Designated as safety issue: No ]
  • The percentage of subjects who experience thrombus formation on the Percutaneous Coronary Intervention equipment [ Time Frame: During the index Percutaneous Coronary Intervention procedure ] [ Designated as safety issue: No ]
  • The percentage of subjects who experience an Myocardial Infarction due to the Percutaneous Coronary Intervention equipment procedure [ Time Frame: During the index Percutaneous Coronary Intervention procedure ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01442792 on ClinicalTrials.gov Archive Site
  • Bleeding (Thrombolysis in Myocardial Infarction major, minor and Bleeding academic research consortium type 2, 3 and 5) [ Time Frame: Up to 30 days post index Percutaneous coronary intervention procedure ] [ Designated as safety issue: Yes ]
  • Composite of clinical ischemic events (all death, non-fatal Myocardial Infarction, non-fatal stroke and target lesion revascularization [ Time Frame: Up to 30 days post index Percutaneous coronary intervention procedure ] [ Designated as safety issue: Yes ]
  • Coagulation profile of Rivaroxaban (Activated Partial Thromboplastin Time) [ Time Frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) ] [ Designated as safety issue: No ]
  • Coagulation profile of Rivaroxaban (Prothrombin time) [ Time Frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) ] [ Designated as safety issue: No ]
  • Coagulation profile of Rivaroxaban (Thrombin Time) [ Time Frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) ] [ Designated as safety issue: No ]
  • Coagulation profile of Rivaroxaban (Prothrombin Fragment 1+2) [ Time Frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) ] [ Designated as safety issue: No ]
  • Coagulation profile of Rivaroxaban (Thrombin Anti-thrombin III Complexes) [ Time Frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) ] [ Designated as safety issue: No ]
  • Coagulation profile of Rivaroxaban (Anti-Xa Activity) [ Time Frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) ] [ Designated as safety issue: No ]
  • Coagulation profile of Rivaroxaban (endogenous thrombin potential) [ Time Frame: 1 to 5 days prior percutaneous coronary intervention (PCI) and the day of PCI (from 2-4 h pre PCI until 48h post PCI or discharge of patient if earlier) ] [ Designated as safety issue: No ]
  • Plasma concentration of Rivaroxaban [ Time Frame: The day of percutaneous coronary intervention (PCI) (from 2 to 4 hours before to 6-8 hours after PCI) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention
Prospective, Multi-center, Randomized, Heparin-controlled Dose-finding Trial to Evaluate the Efficacy and Safety of Rivaroxaban, a Direct Factor Xa Inhibitor, on the Background of Standard Dual Antiplatelet Therapy to Support Elective Percutaneous Coronary Intervention

Balloon angioplasty (Percutaneous Coronary Intervention (PCI)) is commonly used to treat patients with obstructive coronary artery disease (CAD). Although PCI is highly effective for the management of CAD, it can potentiate an existing prothrombotic state around lesion areas. A certain level of anticoagulation is required to perform planned PCI safely and to minimize the periprocedural risk of thrombosis and its attendant complications, including myocardial ischemia and infarction (heart attack). Many different anti-thrombotic regimens have been investigated and are currently in use. The aim of this study is to explore whether Rivaroxaban, as compared to unfractionated heparin, on the background of standard dual antiplatelet therapy, can effectively suppress thrombosis and related adverse ischemic events, upon balloon inflation and stent expansion, during elective PCI, without increasing bleeding. The treatment assignment will be done in a semi-blinded design, eg, no blinding for randomization either to Rivaroxaban (one of the three arms) or the control (UFH) group. However, all will be blinded for the treatment dose of rivaroxaban (either 10mg or 20 mg).The 10 mg rivaroxaban plus 50 IU UFH arm will not be blinded.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Masking: Open Label
Primary Purpose: Prevention
Cardiovascular Disease, Coronary Artery Disease
  • Drug: UFH
    Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
  • Drug: Rivaroxaban (Xarelto, BAY59-7939)
    10 mg single dose Rivaroxaban (per os)
  • Drug: Rivaroxaban (Xarelto, BAY59-7939)
    20 mg single dose Rivaroxaban (per os)
  • Drug: Rivaroxaban (Xarelto, BAY59-7939) and UFH
    10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)
  • Active Comparator: Arm 1
    Intervention: Drug: UFH
  • Experimental: Arm 2
    Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)
  • Experimental: Arm 3
    Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939)
  • Experimental: Arm 4
    Intervention: Drug: Rivaroxaban (Xarelto, BAY59-7939) and UFH
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
108
March 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female subject aged 18 years or more with no upper age limit and willing to comply with the protocol
  • Symptomatic coronary artery disease due to undergo an elective (non-emergent) Percutaneous Coronary Intervention (PCI) on one or two lesions in the native coronary vessel(s). Cardiac standard troponin at baseline is within the normal limits

Exclusion Criteria:

  • Conditions that may increase the risk of the PCI procedure
  • Conditions that may increase the risk of bleeding
  • Significant valvular heart disease
  • Calculated creatinine clearance ≤30 mL/min
  • Current use of anticoagulant drugs including Vitamin K antagonist (VKA), factor IIa or factor XA inhibitors
  • Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs)
  • Chronic treatment with aspirin > 100mg
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Netherlands
 
NCT01442792
15572, 2011-001094-58
Yes
Bayer
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP